Prestige Consumer Healthcare Inc. (PBH)
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
- Symbol
- PBH
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $2.27B
- 52 week range
- 42.62 - 71.07
Valuation
- Share price
- $45.92 (close of 2026-09-23)
- P/E (TTM)
- 13.33x
- Price to book
- 1.18x
- Price to free cash flow
- 9.63x
- Enterprise value
- $4.24B
- Book value per share
- $40.38
Price performance
| Period | Change |
|---|
| 1 day | -1.88% |
| 5 days | -1.63% |
| 1 month | -10.50% |
| 3 months | -0.28% |
| 6 months | -26.86% |
| Year to date | -25.56% |
| 1 year | -27.09% |
| 3 years | -20.04% |
| 5 years | -13.70% |
| 10 years | -2.67% |
| All time | +158.70% |
Profitability and growth
- Return on equity
- 10.08%
- Return on invested capital
- 8.44%
- Return on assets
- 5.45%
- Return on capital employed
- 9.17%
- Gross margin
- 54.71%
- Net margin
- 17.48%
- EBITDA margin
- 31.29%
- Revenue growth
- -4.31%
- Net income growth
- -11.32%
- Free cash flow growth
- 1.30%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 10.39%
- Current ratio
- 3.23x
- Net debt to EBITDA
- 6.33x
Latest reported year
- Period end
- 2026-03-31
- Fiscal year
- 2026
- Revenue
- $1.09B
- Cost of revenue
- $493.13M
- Gross profit
- $595.58M
- EBITDA
- $340.68M
- Net income
- $190.30M
- Earnings per share
- $3.93
- Shares outstanding
- 48.46M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2026-03-31 | $1.09B | $595.58M | $190.30M | $3.93 |
| 2025-03-31 | $1.14B | $634.46M | $214.60M | $4.32 |
| 2024-03-31 | $1.13B | $624.45M | $209.34M | $4.21 |
| 2023-03-31 | $1.13B | $625.29M | $-82.31M | $-1.65 |
| 2022-03-31 | $1.09B | $620.65M | $205.38M | $4.09 |
| 2021-03-31 | $943.37M | $547.47M | $164.68M | $3.28 |
| 2020-03-31 | $963.01M | $552.22M | $142.28M | $2.81 |
| 2019-03-31 | $975.78M | $555.58M | $-35.80M | $-0.69 |
| 2018-03-31 | $1.04B | $576.50M | $339.57M | $6.40 |
| 2017-03-31 | $882.06M | $500.29M | $69.39M | $1.31 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2026-03-31 | 54.71% | 17.48% | 10.08% | 8.44% |
| 2025-03-31 | 55.76% | 18.86% | 11.70% | 9.61% |
| 2024-03-31 | 55.49% | 18.60% | 12.65% | 10.03% |
| 2023-03-31 | 55.45% | -7.30% | -5.69% | -0.41% |
| 2022-03-31 | 57.11% | 18.90% | 13.02% | 8.93% |
| 2021-03-31 | 58.03% | 17.46% | 12.12% | 9.08% |
| 2020-03-31 | 57.34% | 14.77% | 12.15% | 8.52% |
| 2019-03-31 | 56.94% | -3.67% | -3.27% | 2.35% |
| 2018-03-31 | 55.37% | 32.61% | 28.81% | 6.86% |
| 2017-03-31 | 56.72% | 7.87% | 8.44% | 5.52% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2026-03-31 | $63.87M | $993.95M |
| 2025-03-31 | $97.88M | $992.36M |
| 2024-03-31 | $46.47M | $1.13B |
| 2023-03-31 | $58.49M | $1.35B |
| 2022-03-31 | $27.18M | $1.48B |
| 2021-03-31 | $32.30M | $1.48B |
| 2020-03-31 | $94.76M | $1.73B |
| 2019-03-31 | $27.53M | $1.80B |
| 2018-03-31 | $32.55M | $1.99B |
| 2017-03-31 | $41.85M | $2.19B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2026-03-31 | $246.45M | $10.84M |
| 2025-03-31 | $243.29M | $11.16M |
| 2024-03-31 | $239.38M | $14.01M |
| 2023-03-31 | $221.93M | $12.40M |
| 2022-03-31 | $250.28M | $9.04M |
| 2021-03-31 | $213.36M | $8.54M |
| 2020-03-31 | $202.56M | $7.64M |
| 2019-03-31 | $178.80M | $7.44M |
| 2018-03-31 | $197.58M | $8.91M |
| 2017-03-31 | $145.69M | $8.15M |
Dividend history
- Most recent payment
- 2018-09-27
| Payment date | Dividend per share |
|---|
| 2018-09-27 | $0.47 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-05
- Consensus EPS estimate
- $1.06
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-06 | Jun/2026 | $0.89 |
| 2026-05-13 | - | - |
| 2026-02-05 | - | - |
| 2025-11-06 | - | - |
| 2025-08-07 | - | - |
| 2025-05-08 | - | - |
| 2025-02-06 | - | - |
| 2024-11-07 | - | - |
Filings and sources
- Company website
- prestigebrands.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Zoetis Inc. (ZTS) · Viatris Inc (VTRS) · Hims & Hers Health, Inc. (HIMS) · Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades